Encompass Health Corp
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Not applicable.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ENCOMPASS HEALTH CORPORATION | |
| By: | /s/ MARK J. TARR |
| Mark J. Tarr | |
| President and Chief Executive Officer | |
| Date: | February 28, 2025 |
[Signatures continue on the following page]
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints Patrick Darby his true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him in his name, place and stead, in any and all capacities, to sign any and all amendments to this Report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Capacity | Date |
|---|---|---|
| /s/ MARK J. TARR | President and Chief Executive Officer and Director | February 28, 2025 |
| Mark J. Tarr | ||
| /s/ DOUGLAS E. COLTHARP | Executive Vice President and Chief Financial Officer | February 28, 2025 |
| Douglas E. Coltharp | ||
| /s/ ANDREW L. PRICE | Chief Accounting Officer | February 28, 2025 |
| Andrew L. Price | ||
| /s/ GREG D. CARMICHAEL | Chairman of the Board of Directors | February 28, 2025 |
| Greg D. Carmichael | ||
| /s/ Edward M. CHRISTIE III | Director | February 28, 2025 |
| Edward M. Christie III | ||
| /s/ JOAN E. HERMAN | Director | February 28, 2025 |
| Joan E. Herman | ||
| /s/ LESLYE G. KATZ | Director | February 28, 2025 |
| Leslye G. Katz | ||
| /s/ PATRICIA A. MARYLAND | Director | February 28, 2025 |
| Patricia A. Maryland | ||
| /s/ KEVIN J. O’CONNOR | Director | February 28, 2025 |
| Kevin J. O’Connor | ||
| /s/ CHRISTOPHER R. REIDY | Director | February 28, 2025 |
| Christopher R. Reidy | ||
| /s/ NANCY M. SCHLICHTING | Director | February 28, 2025 |
| Nancy M. Schlichting | ||
| /s/ TERRANCE WILLIAMS | Director | February 28, 2025 |
| Terrance Williams | ||
Item 15. Financial Statements
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-2 |
|---|---|
| Consolidated Statements of Comprehensive Income for each of the years in the three-year period endedDecember 31, 2024 | F-5 |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Shareholders’ Equity for each of the years in the three-year period endedDecember 31, 2024 | F-7 |
| Consolidated Statements of Cash Flows for each of the years in the three-year period endedDecember 31, 2024 | F-8 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.